TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03287011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoplaq toothpaste
Description: ACTIVE INGREDIENT Sodium Monofluorophosphate 1000 PPM INGREDIENTS Precipitated Calcium Carbonate, Sorbitol, Glycerin, Precipitated Silica, Sodium Carboxy Methyl Cellulose, Sodium Benzoate, DM Water, Colour CI-45410, Holy Basil Oil, Neem Oil, Citrus Oil, Thymol Oi, Clove Oil, Piper Betel Leaf Oil, Tea Tree Oil, Eucalyptus Oil, Peppermint Oil, Spearmint Oil.~Dye containing tooth paste for disclosing plaque and efficient brushing for better oral health.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate toothpaste
Description: fluoridated
Study: NCT02839382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie
Study: NCT02808247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
Study: NCT01889069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
Study: NCT00830687

Intervention type: DEVICE
Group type: OTHER
Intervention: TARGON FN
Description: The Targon FN implant consists of a small side plate with six locking screw ports
Study: NCT02528851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation from endotracheal mechanical ventilation to CPAP
Description: Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extubation from endotracheal mechanical ventilation to CPAP
Description: Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation.
Study: NCT01426347

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sugar pill
Description: Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: Ergocalciferol 50,000 IU per week for 16 weeks
Study: NCT02839382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Outreach
Description: Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Outreach
Description: Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Site Visits
Description: Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Site Visits
Description: Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities.
Study: NCT01456364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients \< 75 years or a 5 mg maintenance dose per day for patients \>= 75 years
Study: NCT00840697

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercises and work related rehabilitation
Description: Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention
Description: 1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary exercise group
Description: 10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
Study: NCT01385956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM 230 LAR
Description: We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Fixed dose: 1000mg/m\^2 weekly x3 then 1 week off
Study: NCT01887678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel® / Zeel® Injectable Solution
Description: Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an injection of Saline
Study: NCT01728571

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Study: NCT01426347

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ergocalciferol
Description: Ergocalciferol 50,000 IU per week for 16 weeks
Study: NCT01727869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT01774136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced HIV and MCH training for CHW
Study: NCT03833895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: 0.05ug/kg/min Norepinephrine during Cesarean Section Operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: 0.25ug/kg/min phenylephrine during Cesarean Section Operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's Solution
Description: 3 ml/kg/min of LR was administrated according to standard weight.
Study: NCT00736411

Intervention type: PROCEDURE
Group type: OTHER
Intervention: acupuncture
Description: 16 treatments over 8 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: one 4 week IVF cycle
Study: NCT01715207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren

Intervention type: DRUG
Group type: OTHER
Intervention: Atenolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Study: NCT02590471

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty with stenting of the femoral artery
Description: A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon extpandable or self-expanding) of all the extension is mounted.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty with stenting of the femoral artery, supplemented by fasciotomy in Hunter's channel
Description: Standard endovascular stenting of femoral artery. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months.
Study: NCT00445575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
Study: NCT04455607

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: perturbation training
Description: A Randomized control trial we will compare two perturbation motor learning paradigms with different challenge level of the practice condition (i.e. blocked practice vs random practice). According to motor learning theory we hypothesize that a) healthy older adults will benefit more from random practice. The purpose of this stage is to investigate the effects of task practice order (random vs blocked) on motor learning (i.e. responding to perturbations during walking) in older adults. According to motor learning theory we hypothesize that a) healthy older adults will benefit more from the random motor learning approach as compared to using blocked practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perturbation training
Description: A Randomized control trial we will compare two perturbation motor learning paradigms with different challenge level of the practice condition (i.e. blocked practice vs random practice). According to motor learning theory we hypothesize that a) healthy older adults will benefit more from random practice. The purpose of this stage is to investigate the effects of task practice order (random vs blocked) on motor learning (i.e. responding to perturbations during walking) in older adults. According to motor learning theory we hypothesize that a) healthy older adults will benefit more from the random motor learning approach as compared to using blocked practice.
Study: NCT02496598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro Follicle Activation (IVA)
Description: Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Activation
Description: Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
Study: NCT02335645

Intervention type: OTHER
Intervention: Body Weight Supported Treadmill Use of Patients with ACL Reconstruction
Description: Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.~The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.~Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.~At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture.
Study: NCT02230462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Viewing of cancer excision defect
Description: Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
Study: NCT01688310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gomco Clamp with Tissue Adhesive
Description: According to WHO (2011), the Gomco clamp has ...an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgical circumcision
Description: The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
Study: NCT02121912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FPH Pilairo Q CPAP mask
Description: CPAP nasal-pillow mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Any other market released nasal or nasal-pillow CPAP mask
Description: Any other market released nasal or nasal-pillow CPAP mask
Study: NCT02842983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: conventional management plus esmolol infusion
Study: NCT03739372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized tumor board recommendation
Description: Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized tumor board recommendation
Description: Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
Study: NCT03667937

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CUTIMED
Description: Hydrophobic Dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL silver
Description: Silver Dressing
Study: NCT01190722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: 120 mg once daily for the 1st 6 postoperative days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 50 mg oral 3 times daily the 1st 6 postoperative days
Study: NCT02132715

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KAATSU exercise
Study: NCT04643093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: Pitavastatin, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1PC111
Description: 1PC111, QD
Study: NCT00311246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
Study: NCT01466790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 will be administered as one oral capsule of 150 mg once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 will be administered as one oral capsule of 150 mg once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 will be administered as one oral capsule of 150 mg once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 will be administered as one oral capsule of 150 mg once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977 (GS7977)
Description: PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977 (GS7977)
Description: PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977 (GS7977)
Description: PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977 (GS7977)
Description: PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
Study: NCT01728571

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Study: NCT00356759

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
Description: Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
Study: NCT00936598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: Participants will receive the FDA approved dose of zolpidem, (10 mg for women \<65; 5 mg for women = or \> 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.